5 Most Promising Healthcare Stocks According to Analysts

2. Royalty Pharma plc (NASDAQ:RPRX)

Average Analyst Price Target Upside: 70.93%

Average Analyst Price Target: $46.75

Royalty Pharma plc (NASDAQ:RPRX) is one of the largest buyers of biopharmaceutical royalties of future drugs from biotech companies and academic labs.

On November 13, Royalty Pharma plc (NASDAQ:RPRX) announced that it would fund Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s antipsychotic candidate, Olanzapine LAI’s (TEV-‘749) studies for up to $125 million. After the candidate is commercialized, the company will receive the funding amount back and low to mid-single-digit royalties.

According to Insider Monkey’s database, 31 hedge funds held a stake in Royalty Pharma plc (NASDAQ:RPRX)’s stock in the third quarter. Phill Gross And Robert Atchinson’s Adage Capital Management was the most significant stakeholder in the company. It increased its stake by 14% to 9.84 million shares worth $267 million. 

Over the last three months, 4 Wall Street analysts covered Royalty Pharma plc (NASDAQ:RPRX), and all kept a Buy rating on the stock. At the time of writing on December 18, the average price target of $46.75 had an upside of 70.93%.

Follow Royalty Pharma Plc (NASDAQ:RPRX)